Skip to content
value.today

Tyton Biosciences LLC

Total raised
$29 M
2 rounds on record
Latest round
$25 M
Nov 2022
First round on record
Jul 2019
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tyton Biosciences LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$25 MNo. 2$10 to $50 million

Tyton Biosciences LLC: Raise no. 2, Nov 2022

Investors in this round

8 investors had bought by the notice of Mar 20, 2023: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher W Austin · Executive Officer
  • Conor W Hartman · Executive Officer
  • Julie W Willoughby · Executive Officer
  • Luke W Henning · Executive Officer
  • Peter Majeranowski · Executive Officer, Director
  • Edward W Scott, Jr. · Director
  • Greg Curtis · Director
  • Libby W Wayman · Director
  • Yasutaka W Nishimune · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director, manager or promoter will receive any payments from the proceeds of this offering.”

Signed by Peter Majeranowski, Ceo. Source: SEC Form D, newest notice filed Mar 20, 2023. Read the notice at the SEC.

equitySEC
Jul 2019$4 MNo. 1$2 to $10 million

Tyton Biosciences LLC: Raise no. 1, Jul 2019

Investors in this round

11 investors had bought by the notice of Aug 1, 2019: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $11 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Luke Henning · Executive Officer
  • Peter Majeranowski · Executive Officer, Director
  • Edward Scott, Jr. · Director
  • Greg Curtis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering.”

Signed by Luke Henning, Cfo. Source: SEC Form D, newest notice filed Aug 1, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tyton Biosciences LLC chose not to state its revenue in its newest notice of a funding round (Mar 2023).

    SEC Form D · Mar 2023

  • The industry group it chose in its notices: Other.

    SEC Form D · Mar 2023

That is all the official record says: Tyton Biosciences LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Tyton Biosciences LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tyton Biosciences LLC
NameRoleNamed in
Christopher W AustinExecutive officerMar 2023
Conor W HartmanExecutive officerMar 2023
Julie W WilloughbyExecutive officerMar 2023
Luke W HenningExecutive officerMar 2023
Peter MajeranowskiExecutive officerMar 2023
Luke HenningExecutive officerAug 2019
Edward W Scott, Jr.DirectorMar 2023
Greg CurtisDirectorMar 2023
Libby W WaymanDirectorMar 2023
Peter MajeranowskiDirectorMar 2023
Yasutaka W NishimuneDirectorMar 2023
Edward Scott, Jr.DirectorAug 2019